Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-11-21 00:00:00 ET · period of report 2022-11-17 · accession 0000899243-22-036575 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-21 | 2022-11-17 | LGND | HIGGINS JOHN L | CEO, Dir | S - Sale+OE | $78.32 | -10.0K | 416.7K | -2% | -$783.2K |
| D | 2022-11-21 | 2022-11-18 | LGND | HIGGINS JOHN L | CEO, Dir | M - OptEx | $12.78 | +10.0K | 426.7K | +2% | +$127.8K |
| D | 2022-11-21 | 2022-11-18 | LGND | HIGGINS JOHN L | CEO, Dir | M - OptEx | $0.00 | -10.0K | 40.3K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-17 | S | D | 10,000 | $78.32 | 416,731 | D | — | — | |
| 2 | Common | Common Stock | 2022-11-18 | M | A | 10,000 | $12.78 | 426,731 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-11-18 | M | D | 10,000 | $0.00 | 40,335 | D | $12.78 · — to 2023-02-15 | 10,000 Common Stock | (F2) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The original date of grant was 02/15/13. |